{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:01:57Z","timestamp":1790182917825,"version":"4.1.0"},"reference-count":18,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Foundation Dam","award":["389462"],"award-info":[{"award-number":["389462"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the progression of newly diagnosed breast cancer patients towards cardioembolic disorders (CDs) and ischaemic or structural heart disease (ISH) within a multistate framework that includes death as an absorbing state, in order to evaluate long-term cardiovascular burden and to examine whether the observed patterns may reflect short-term acute events or longer-term effects potentially associated with treatment. CD and ISH occurrences following breast cancer treatment may have different underlying biological mechanisms, potentially leading to different survival patterns across patient groups defined by breast cancer characteristics, and we sought to explore this.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Two continuous-time multistate Markov models described patients\u2019 transitions among three states: time of breast cancer diagnosis, first occurrence of CD or ISH, and death, depending on patients\u2019 molecular subtype, tumour stage, age and radiation treatment status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Altogether 36\u2009778 patients from the Norwegian Cancer Registry, linked with information on cardiovascular events from the Norwegian Patient Registry, diagnosed earliest in 2006, followed until their first cardiovascular event and\/or death or throughout 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HR\u2212\/HER2\u2212 patients had the highest HR for a first CD event compared with HR+\/HER2\u2212 patients (HR 1.51, 95%\u2009CI 1.39 to 1.65), with no significant differences observed between the remaining groups. For first ISH event, HR\u2212\/HER2+, HR+\/HER2+ and HR\u2212\/HER2\u2212 patients had HRs of 1.91 (95% CI 1.61 to 2.27), 1.64 (95% CI 1.43 to 1.88) and 1.56 (95% CI 1.44 to 1.69), respectively, compared with HR+\/HER2\u2212 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term cardiovascular burden for patients with breast cancer may be more strongly influenced by chronic vascular and myocardial damage, likely driven by treatment-related cardiotoxicity and cumulative exposure compared with acute thromboembolic mechanisms. A multistate Markov modelling approach proved valuable for capturing the dynamics for patients to move between the states breast cancer diagnosis, CD or ISH event and death, and may guide more tailored follow-up and use of cardioprotective strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117647","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:25Z","timestamp":1790179825000},"page":"e117647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular events and mortality after breast cancer diagnosis: multistate models in a nationwide cohort study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-5486","authenticated-orcid":false,"given":"Ingunn Fride","family":"Tvete","sequence":"first","affiliation":[{"name":"Statistical Modelling and Machine Learning, Norwegian Computing Center, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Klemp","sequence":"additional","affiliation":[{"name":"Retired, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092309101350000_16.9.e117647.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0409"},{"key":"2026092309101350000_16.9.e117647.2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa096"},{"key":"2026092309101350000_16.9.e117647.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.04.002"},{"key":"2026092309101350000_16.9.e117647.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp440"},{"key":"2026092309101350000_16.9.e117647.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014944","article-title":"Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom","volume":"7","author":"Vaidya","year":"2017","journal-title":"BMJ Open"},{"key":"2026092309101350000_16.9.e117647.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01904-5"},{"key":"2026092309101350000_16.9.e117647.7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4048\/jbc.2025.0151","article-title":"Investigating Time-Varying Predictor Effects on Cardiovascular Outcomes in Breast Cancer Survivors","volume":"29","author":"Tvete","year":"2026","journal-title":"J Breast Cancer"},{"key":"2026092309101350000_16.9.e117647.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0349115","article-title":"Temporal dynamics of prognostic factors in breast cancer survival","volume":"21","author":"Tvete","year":"2026","journal-title":"PLoS One"},{"key":"2026092309101350000_16.9.e117647.9","unstructured":"Cancer registry of Norway. n.d. Available: https:\/\/www.fhi.no\/en\/cancer\/"},{"key":"2026092309101350000_16.9.e117647.10","unstructured":"The Norwegian patient registry. n.d. Available: https:\/\/helsedata.no\/en\/forvaltere\/norwegian-institute-of-public-health\/norwegian-patient-registry-npr\/"},{"key":"2026092309101350000_16.9.e117647.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024299","article-title":"Risk Factors, Subsequent Disease Onset, and Prognostic Impact of Myocardial Infarction and Atrial Fibrillation","volume":"11","author":"Camen","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026092309101350000_16.9.e117647.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308407"},{"key":"2026092309101350000_16.9.e117647.13","doi-asserted-by":"crossref","unstructured":"Jackson C . Multi-state models for panel data: the msm package for R. J Stat Softw 2011;1\u201329. doi:10.18637\/jss.v038.i08","DOI":"10.18637\/jss.v038.i08"},{"key":"2026092309101350000_16.9.e117647.14","unstructured":"National action program with guidelines for diagnosis, treatment and follow-up of patients with breast cancer. n.d. Available: https:\/\/www.helsedirektoratet.no\/retningslinjer\/brystkreft-handlingsprogram"},{"key":"2026092309101350000_16.9.e117647.15","unstructured":"R software: rstudio team . RStudio: integrated development for R. RStudio, PBC, Boston, MA. 2020. Available: http:\/\/www.rstudio.com\/"},{"key":"2026092309101350000_16.9.e117647.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01469-w","article-title":"Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer","volume":"23","author":"Leoce","year":"2021","journal-title":"Breast Cancer Res"},{"key":"2026092309101350000_16.9.e117647.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105128","article-title":"Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care","volume":"10","author":"Dauccia","year":"2025","journal-title":"ESMO Open"},{"key":"2026092309101350000_16.9.e117647.18","doi-asserted-by":"crossref","DOI":"10.3390\/medsci13030130","article-title":"Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies","volume":"13","author":"Fitrianti","year":"2025","journal-title":"Med Sci (Basel)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:29Z","timestamp":1790179829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-117647"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117647","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}